BPG is committed to discovery and dissemination of knowledge
Featured Articles
11/21/2014 8:18:00 AM | Browse: 905 | Download: 1136
Publication Name World Journal of Clinical Urology
Manuscript ID 10984
Country Japan
Received
2014-04-29 14:25
Peer-Review Started
2014-04-30 13:35
To Make the First Decision
2014-06-18 18:33
Return for Revision
2014-06-19 11:48
Revised
2014-06-26 12:55
Second Decision
2014-07-29 09:00
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-07-29 09:12
Articles in Press
2014-07-29 09:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-08-07 16:33
Typeset the Manuscript
2014-11-17 08:44
Publish the Manuscript Online
2014-11-19 17:43
ISSN 2219-2816 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Urology & Nephrology
Manuscript Type Review
Article Title Review of novel therapeutic medicines targeting androgen signaling in castration-resistant prostate cancer
Manuscript Source Invited Manuscript
All Author List Daisuke Obinata, Kyoko Fujiwara, Kenya Yamaguchi, Ken-ichi Takayama, Tomohiko Urano, Hiroki Nagase, Satoshi Inoue, Satoru Takahashi and Noboru Fukuda
Funding Agency and Grant Number
Corresponding Author Noboru Fukuda, MD, PhD, Division of Life Science, Advanced Research Institute of Sciences and Humanities, Nihon University, 30-1 Ooyaguchikamimachi, Itabashi, Tokyo 173-8610, Japan. fukuda.noboru@nihon-u.ac.jp
Key Words Androgen receptor; Prostate cancer; Pyrrole-imidazole polyamide
Core Tip Prostate cancer is the most common male malignant neoplasm. Androgens and the androgen receptor (AR) play a key role in the onset and progression of prostate cancer. The expression of the AR is still preserved in the majority of patients with castration-resistant prostate cancer (CRPC). Therefore, identification of the AR signaling pathways responsible for establishment of CRPC is critical for developing new strategies for the treatment of CRPC.
Publish Date 2014-11-19 17:43
Citation Obinata D, Fujiwara K, Yamaguchi K, Takayama K, Urano T, Nagase H, Inoue S, Takahashi S, Fukuda N. Review of novel therapeutic medicines targeting androgen signaling in castration-resistant prostate cancer. World J Clin Urol 2014; 3(3): 264-271
URL http://www.wjgnet.com/2219-2816/full/v3/i3/264.htm
DOI http://dx.doi.org/10.5410/wjcu.v3.i3.264
Full Article (PDF) WJCU-3-264.pdf
Full Article (Word) WJCU-3-264.doc
Manuscript File 10984-Review.docx
Answering Reviewers 10984-Answering reviewers.pdf
Copyright License Agreement 10984-Copyright assignment.pdf
Peer-review Report 10984-Peer review(s).pdf
Scientific Misconduct Check 10984-CrossCheck.jpg
Scientific Editor Work List 10984-Scientific editor work list.pdf